Medical management of secondary hyperparathyroidism in Uremia

American Journal of the Medical Sciences

Volumn 317, Issue 6, 1999, Pages 383-389

  Drüeke, Tilman B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Chronic renal failure; Hyperparathyroidism, secondary; Treatment

Indexed keywords

ALCOHOL; ALFACALCIDOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SALT; MAGNESIUM SALT; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; DERIVATIZATION; DRUG EFFECT; HUMAN; KIDNEY FAILURE; PHOSPHATE INTAKE; PROTEIN INTAKE; SECONDARY HYPERPARATHYROIDISM; TREATMENT INDICATION; UREMIA;

EID: 0342657125     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40551-8     Document Type: Conference Paper

References (51)

1. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-63.
2. Fournier A, Oprisiu R, Yverneau-Hardy P, et al. What is the optimal range for plasma concentrations of intact parathyroid hormone in uremic patients? Ital J Miner Electrol Metab 1995;9:95-101.
3. Felsenfeld AJ. Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephrol 1997;8:993-1004.
4. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47: 1434-42.
5. Fournier A, Oprisiu R, Esper NE, et al. Optimal plasma concentrations of intact parathyroid hormone in predialysis patients [letter]. Nephrol Dial Transplant 1995;10: 2376-7.
6. Kanis JA. Vitamin D analogs: from renal bone disease to osteoporosis. Calcif Tissue Int 1995;60:106-10.
7. Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992;43:227-37.
8. 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989;35:661-9.
9. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis renal failure. J Clin Endocrinol Metab 1988;67:937-41.
10. Ritz E, Küster S, Schmidt-Gayk H, et al. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicenter trial). Nephrol Dial Transplant 1995;10:2228-34.
11. Panichi V, Andreini B, DePietro S, et al. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialysis renal failure. Clin Nephrol 1998; 49:245-50.
12. 3 and 25 (OH) vitamin D3. Kidney Int 1998;33(Suppl 24):S178-9.
13. Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 1991;17:708-11.
14. Lafage M-H, Combe C, Fournier A, et al. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992;42:1217-25.
15. Fukagawa M, Kitaoka M, Yi H, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68:221-8.
16. Drücke T. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995;48:259-72.
17. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997;52:3-9.
18. Cunningham J, Makin H. How important is vitamin D deficiency in uraemia [editorial comment]? Nephrol Dial Transplant 1997;12:16-8.
19. Atik A, Ghazali A, Achard JM, et al. La déplétion relative en vitamine D native: un facteur de risque potentiel chez l'hémodialysé algérien de lésions radiologiques d'hyperparathyroïdie et d'ostéomalacie indépendant de la calcitriolémie. Néphrologie 1997;18:47-52.
20. Fournier A, Bordier P, Guéris J, et al. Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 1979;15:196-204.
21. Eastwood JB, Harris E, Stamp TCB, et al. Vitamin D deficiency in the osteomalacia of chronic renal failure. Lancet 1976;2:1209-11.
22. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993; 40:216-20.
23. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45: 1710-21.
24. Lee WT, Padayachi F, Collins JF, et al. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol 1994;5:1344-8.
25. Bacchini G, Fabrizi F, Pontoriero G, et al. Pulse oral versus intravenous calcitriol therapy in chronic hemodialysis patients - a prospective and randomized study. Nephron 1997;77:267-72.
26. Peng SJ, Yang CS, Ferng SH, et al. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab 1997;23: 13-8.
27. Herrmann P, Ritz E, Schmidt-Gayk H, et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994;67:48-53.
28. Canella G, Bonucci E, Rolla D, et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994;46:1124-32.
29. Sawyer N, Nooman K, Altman P. High dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 1989;4: 105-9.
30. Slatopolsky E, Weerts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989;36:897-903.
31. Teruel JL, Nitvarro JF, Marcen R, et al. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D. Miner Electrolyte Metab 1997;23:19-24.
32. Argilés A, Kerr PG, Canaud B, et al. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993;43:630-40.
33. Fernandez E, Borras M, Pais B, et al. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hypoparathyroidism. J Am Soc Nephrol 1995;6:132-5.
34. Cunningham J, Beer J, Coldwell RD, et al. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992;7: 63-8.
35. Chagnac A, Ori Y, Weinstein T, et al. Hypercalcemia during pulse vitamin D3 therapy in CAPD patients treated with low calcium dialysate - the role of the decreasing serum parathyroid hormone level. J Am Soc Nephrol 1997;8:1579-86.
36. Ghazali A, Hamida FB, Bouzernidj M, et al. Management of hyperphosphatemia in patients with renal failure. Curr Opin Nephrol Hypertens 1993;2:566-79.
37. Schaefer K. Unsatisfactory control of serum phosphate: why is it so common and what can be done? Nephrol Dial Transplant 1994;9:1366-7.
38. Lefebvre A, Vernejoul MCD, Gueris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989;36:1112-8.
39. Graham KA, Hoenich NA, Tarbit M, et al. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 1997; 8:627-31.
40. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-4.
41. Slatopolsky EA, Burke SK, Dillon MA. RenaGel®, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307.
42. Fournier A, Morinière P, Oprisiu R, et al. 1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 1995;71:254-83.
43. Tan AU, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23.
44. Brown EM, Pollak M, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+ -sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism [editorial]. Nephrol Dial Transplant 1994;9:1703-6.
45. Wada M, Furuya Y, Sakiyama J, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1997;53: 448-53.
46. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100: 2977-83.
47. Silverberg S, Bone HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. New Engl J Med 1997;337:1506-10.
48. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure - rapid communication. Kidney Int 1998;53:223-7.
49. Collins JT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83: 1083-8.
50. Giangrande A, Castiglioni A, Solbiati L, et al. US-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992;7:412-20.
51. Kitakoa M, Fukagawa M, Ogata E, et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994;46: 1110-7.